Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Value from health data

157 views

Published on

Ellie D'Hondth Imec 5th data science leuven meetup

Published in: Data & Analytics
  • Be the first to comment

  • Be the first to like this

Value from health data

  1. 1. INTERNAL – CONFIDENTIAL MAKING HEALTH DATAVALUABLE ELLIE D’HONDT
  2. 2. CONFIDENTIAL — DO NOT SHARE $$$ $$$ THE UNDERPANT GNOMES METAPHOR
  3. 3. CONFIDENTIAL — DO NOT SHARE $$$ $$$ THE UNDERPANT GNOMES METAPHOR DATA VALUE
  4. 4. 4 NICU DATA ANALYTICS FOR CLINICAL DECISION SUPPORT
  5. 5. 5 [Van Laere & al, J. Pediatrics, 178(119-124), 2016]
  6. 6. 6 [Van Laere & al, J. Pediatrics, 178(119-124), 2016] BACKGROUND ?
  7. 7. 1. NICU DATA ANALYTICS: STAKEHOLDERS & INTERACTIONS intervention service 7 EMR platform hospitals medical grade sensor health practitioners patient infrastructure care data monitoring system (PDMS) decisionsupport sensor fusion events centralised UI events real-tim e analytics = hospital context data sharing
  8. 8. PATIENT DATA ANALYTICS FOR IMPROVED HEALTHCARE VEHICLES: DISEASE TRAJECTORIES & OMICS
  9. 9. FEMALE MORTALITY RATE HIGHER AFTER CARDIAC ARREST 180.368 patients with diagnosis of cardiac arrest Sweden, 2003-2013, 73 hospitals survival rates after 1y: ♀ 83%, ♂ 87% survival rates after 5y: ♀ 75%, ♂ 82% i.e. triple risk of death at 1 year and a double risk at 5 years ♀ vs. ♂ confounders considered no diff when following best-practice guidelines why?? speculation so far. 9 Alabas OG et al. Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry Journal of the American Heart Association. Published online December 14 2017
  10. 10. 10 patient stratification fine-grained treatment outcomes fine-grained epidemiology comorbidities ⬌ treatments unexpected treatment effects (+/-) treatment trajectory analysis + omics (gen-, proteo-, metabol-,radi-)
  11. 11. 11 patient stratification fine-grained treatment outcomes fine-grained epidemiology comorbidities ⬌ treatments unexpected treatment effects (+/-) treatment trajectory analysis + omics (gen-, proteo-, metabol-,radi-) adaptive trial design outcome-based reimbursement personalised treatments clinical decision support drug repurposing health expenditure planning prevention strategies
  12. 12. CLINICAL TRIALS TODAY 12 EMR system hospitals health practitioners patient infrastructure care clinical sensors monitoring system (PDMS) events events data extraction pharma clinical research organisation trial design trial execution = hospital context = new
  13. 13. ADAPTIVE CLINICAL TRIALS adaptive trial service new stakeholder 13 EMR system hospitals health practitioners patient infrastructure care clinical sensors monitoring system (PDMS)apps & wearables events events pharma clinical research organisation daily updates initial design & updatestrial execution = new trial execution outside hospital = hospital context wearable platform daily analytics research partners
  14. 14. UTOPIA 14 MedTech government patients hospitals pharma virtual medical wallet mutualiteithealth practitioners pharmacies software engineering clinical trials CRO reim bursem ent care & follow-up care & reimbursement admin &ownership reimbursement & adherence to guidelines trusted intermediary
  15. 15. 15
  16. 16. BARRIERS 16 legacy systems value from data privacy regulation legacy behaviour virtual medical wallet knowledge from data standards governance 16 silos budget
  17. 17. 17
  18. 18. state-of-the-art 300mm cleanroom (2016 – 4000m2) ▪ unique high-tech infrastructure ▪ pre-competitive research ▪ full eco-system ▪ 3500 people ▪ 6 countries
  19. 19. LIFE SCIENCES BODY AREA NETWORKS NERF HIGH PERFORMANCE COMPUTING FOR LIFE SCIENCES
  20. 20. WHOLE GENOME ANALYSIS 20 SAMPLE SEQUENCINGCELL SORTER REPORT GENOME ANALYSIS SOFTWARE GENOME ALIGNMENT SOFTWARE SEQUENCER DATA VARIANT DATA @ IMEC
  21. 21. HIGH PERFORMANCE COMPUTING FOR LIFE SCIENCES

×